... is an uncommon initial manifestation of CML and is typically attributed to the disease itself. However, with the use of tyrosine kinase inhibitors (TKIs), which can affect T-cell-mediated immunity, new or persistent lymphadenopathy in CML patients warrants investigation to rule out opportunistic infections...

... Philadelphia chromosome, containing the BCR::ABL1 fusion gene. The natural history of untreated CML is an initial indolent chronic phase which will be followed by an accelerated phase, blast phase, or both. Tyrosine kinase inhibitors (TKIs) have dramatically altered the natural history of CML. TKI...

... cell neoplasms Histiocytosis Tyrosine kinase inhibitors Positron emission tomography scan Histiocytosis is a spectrum of diseases characterized by the infiltration and accumulation of dendritic cells, macrophages, or monocyte-derived cells in various body tissues and organs. These cells...

...Brittany M. Smith; Diana Brewer; Brian J. Druker; Theodore P. Braun Quantitative PCR-based strategies are typically effective for monitoring BCR-ABL1 transcript levels in chronic myeloid leukemia (CML). Additionally, some patients treated with tyrosine kinase inhibitors can experience long-term...

... individualized. With developments in modern treatment and phase III clinical trial results, epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) and ALK-TKI have proven thier superior effectivity in comparison with the standard platinum-based doublet and are commonly approved as first-line...

... treated with imatinib (tyrosine kinase inhibitor), acute lymphoblastic leukemia protocol (BFM 2009) then shifted to lymphoma protocol (LMP 96). In conclusion, we report a unique rare case of γδ T-cell neoplasm with a combination of mature and immature γδ T-cells and eosinophilia that is inapplicable...

... . 10.1158/1078-0432.CCR-16-0355 . 8. Aroldi   F , Bertocchi   P , Meriggi   F , Abeni   C , Ogliosi   C , Rota   L , et al.   Tyrosine kinase inhibitors in EGFR-mutated large-cell neuroendocrine carcinoma of the lung? A case report . Case Rep Oncol . 2014 Mar ; 7 ( 2 ): 478 – 83...

...Anannya Patwari; Vineel Bhatlapenumarthi; Sheila K. Pascual We report here a rare case of atypical posterior reversible encephalopathy syndrome (PRES) due to oral tyrosine kinase inhibitor cabozantinib. No case reports of such have been found in our literature search. The patient, a 70-year-old...

...Philip T. Sobash; Achuta K. Guddati; Vamsi Kota Chronic myelogenous leukemia (CML) is a hematopoietic disorder caused by the BCR/ABL gene or Philadelphia chromosome. The first Food and Drug Administration (FDA)-approved tyrosine kinase inhibitor for treatment of CML was imatinib in 2001. Since...

...Amirahwaty Abdullah; Manidhar Lekkala; Zachary Wolfe; Charumathi Raghu; Safi Ullah Khan; Mrinalini Krishnan; Lydia Winnicka; Bradley Lash Background: The treatment of metastatic renal cell carcinoma (RCC) has been radically changed by the advent of tyrosine kinase inhibitors (TKIs). However, few...

... stromal tumours Imatinib KIT Tyrosine kinase inhibitors Case Report Case Rep Oncol 2017;10:66 76 DOI: 10.1159/000455188 Published online: January 17, 2017 © 2017 The Author(s) Published by S. Karger AG, Basel www.karger.com/cro This article is licensed under the Creative Commons Attribution...

... ]. Ibrutinib is rapidly metabolized by the hepatic cytochrome P450 3A4 enzyme and to a lesser extent by cytochrome P450 2D6. Tyrosine kinase inhibitors (TKIs), a form of targeted therapy, redefined the oncologic treatment of multiple malignancies, ranging from chronic myelogenous leukemia to subtypes...

...(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Epidermal growth factor receptor mutation Tyrosine kinase inhibitors Gefitinib Large-cell neuroendocrine carcinoma...

... present with advanced disease and effective systemic treatment options are currently limited. Epidermal growth factor (EGFR) mutations may occur in PDTC more often than previously thought. However, there are fewer than 6 cases reported in the literature where EGFR tyrosine kinase inhibitors (TKIs...

... for neurologic findings in hypertensive patients with known metastatic cancers under tyrosine kinase inhibitor therapy. 6 4 2013 © 2013 S. Karger AG, Basel 2013 Open Access License / Drug Dosage / Disclaimer Open Access License: This is an Open Access article licensed under the terms...

...Genovefa Polychronidou; Pavlos Papakotoulas The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are known to have greater efficacy in EGFR mutation-positive non-small cell lung cancer (NSCLC), although erlotinib also has activity in wild-type...